Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06564987 · ClinicalTrials.gov registry record · Phase 1

Risk of Nerve Damage After Administration of Local Anesthesia

A Phase 1 study of Inferior Alveolar Nerve Injuries, sponsored by Cleveland Dental Institute.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
2
Study locations

NCT06564987 is a Phase 1 study of Inferior Alveolar Nerve Injuries that is actively recruiting participants, run by Cleveland Dental Institute. The registered enrollment target is 80 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06564987, a Phase 1 study of Inferior Alveolar Nerve Injuries, is actively recruiting participants, sponsored by Cleveland Dental Institute.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.

Interventions

  • DRUG 4% Articaine with 1:200,000 epinephrine
  • DRUG 2% lidocaine with 1:100,000 epinephrine

Study Locations (2)

Ohio

  • Cleveland Dental Institute - Akron
  • Cleveland Dental Institute - Ashtabula

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-01-01
Est. Completion 2025-03-31
Phase Phase 1

Sponsor

Cleveland Dental Institute

6 total trials

What the Registry Record Tells You About NCT06564987

The ClinicalTrials.gov registry entry for NCT06564987 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cleveland Dental Institute, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Inferior Alveolar Nerve Injuries appearing as the primary indexed condition, and to 2 interventions - of which 4% Articaine with 1:200,000 epinephrine is the first listed.

NCT06564987 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06564987 about?

NCT06564987 is a clinical study titled "Risk of Nerve Damage After Administration of Local Anesthesia". This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% ...

What is the current status of trial NCT06564987?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-01-01. Estimated completion is 2025-03-31.

What conditions does trial NCT06564987 study?

This clinical trial studies the following conditions: Inferior Alveolar Nerve Injuries.

What interventions are being tested in trial NCT06564987?

The interventions under investigation include: 4% Articaine with 1:200,000 epinephrine (DRUG), 2% lidocaine with 1:100,000 epinephrine (DRUG).

Who is sponsoring clinical trial NCT06564987?

This trial is sponsored by Cleveland Dental Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06564987 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.